In the ongoing battle against drug-resistant infections, a new class of antibiotics has emerged as a beacon of hope, pioneered by Kinvard Bio, a Harvard-based biotech startup.With the alarming rise of antibiotic resistance challenging global healthcare systems, these innovative antibiotics promise to address critical gaps in our treatment arsenal.